[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Invivyd Inc (IVVD)

Invivyd Inc (IVVD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 285,739
  • Shares Outstanding, K 294,607
  • Annual Sales, $ 53,430 K
  • Annual Income, $ -52,490 K
  • EBIT $ -82 M
  • EBITDA $ -80 M
  • 60-Month Beta 0.63
  • Price/Sales 5.13
  • Price/Cash Flow N/A
  • Price/Book 1.35
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.31
  • Most Recent Earnings $-0.13 on 05/14/26
  • Next Earnings Date 08/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 236.72% (+30.80%)
  • Historical Volatility 104.59%
  • IV Percentile 81%
  • IV Rank 18.11%
  • IV High 1,010.24% on 06/27/25
  • IV Low 65.69% on 05/19/26
  • Expected Move (DTE 25) 0.4675 (51.37%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2,850
  • Volume Avg (30-Day) 1,091
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 27,301
  • Open Int (30-Day) 28,567
  • Expected Range 0.4425 to 1.3775

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.15
  • Number of Estimates 1
  • High Estimate $-0.15
  • Low Estimate $-0.15
  • Prior Year $-0.12
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7282 +25.57%
on 06/12/26
1.2500 -26.85%
on 06/01/26
-0.1856 (-16.87%)
since 05/22/26
3-Month
0.7282 +25.57%
on 06/12/26
1.8000 -49.20%
on 04/17/26
-0.4656 (-33.74%)
since 03/20/26
52-Week
0.4830 +89.32%
on 08/21/25
3.0699 -70.21%
on 11/17/25
+0.1685 (+22.59%)
since 06/20/25

Most Recent Stories

More News
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

Invivyd expects to report topline data from LIBERTY in Q3 2026 Data from LIBERTY can provide important insight into the VYD2311 clinical profile by direct comparison between COVID antibody prophylaxis...

IVVD : 0.9144 (-5.72%)
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine...

LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA COVID-19 vaccine, as well as explore the safety and immunology of co-administered VYD2311 and mRNA COVID-19...

IVVD : 0.9144 (-5.72%)
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on June 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate...

IVVD : 0.9144 (-5.72%)
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of symptomatic COVID-19 versus placebo, at three months, from a...

IVVD : 0.9144 (-5.72%)
Invivyd to Participate in Upcoming Investor Events

NEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June: 2026 Jefferies Global Healthcare Conference...

IVVD : 0.9144 (-5.72%)
Invivyd Q1 Earnings Call Highlights

Invivyd (NASDAQ:IVVD) said its first quarter of 2026 was marked by continued progress in its pivotal COVID-19 antibody program, year-over-year growth for PEMGARDA and elevated clinical spending tied to...

IVVD : 0.9144 (-5.72%)
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

Achieved Q1 2026 PEMGARDA ® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 million Invivyd in vitro data showed continued neutralizing...

IVVD : 0.9144 (-5.72%)
Invivyd's First Quarter May Show Whether Pemgarda Revenue Can Sustain Momentum—If It Shows Up

Barchart Research What to Expect from IVVD Earnings IVVD Generated May 13, 2026 Current Price $1.4700 EPS Estimate $$-0.08 Consensus Rating Moderate Buy Average Move 6.22% Invivyd's First Quarter May Show...

IVVD : 0.9144 (-5.72%)
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issues Results allow for comparison...

IVVD : 0.9144 (-5.72%)
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

NEW HAVEN, Conn., May 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that...

IVVD : 0.9144 (-5.72%)

Business Summary

INVIVYD INC. is a biopharmaceutical company. It involved in developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. INVIVYD INC., formerly known as Adagio Therapeutics, is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 1.0371
2nd Resistance Point 1.0111
1st Resistance Point 0.9627
Last Price 0.9144
1st Support Level 0.8883
2nd Support Level 0.8623
3rd Support Level 0.8139

See More

52-Week High 3.0699
Fibonacci 61.8% 2.0817
Fibonacci 50% 1.7765
Fibonacci 38.2% 1.4712
Last Price 0.9144
52-Week Low 0.4830

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.